Ongentys (Opicapone)

Ongentys is a COMT inhibitor that addresses motor complications associated with Parkinson's disease therapy.

• Parkinson's disease (wearing‑off): Improves the duration of levodopa effect and reduces daily OFF time.
• Adjunct to levodopa/carbidopa: Enhances overall motor control when added to standard Parkinson's regimens.
• Motor fluctuations: Provides more consistent symptom control throughout the dosing interval.

• Opicapone binds selectively and reversibly to the peripheral enzyme catechol‑O‑methyltransferase, inhibiting the breakdown of levodopa. By reducing peripheral levodopa metabolism, higher and more stable plasma concentrations reach the brain, allowing continuous dopaminergic stimulation and smoother motor function in Parkinson's disease patients.

Adverse reactions reported with Opicapone are generally mild to moderate and reflect its pharmacologic activity and formulation.

Common Side Effects

• Dyskinesia: Increased involuntary movements, especially when combined with levodopa.
• Nausea: Mild to moderate gastrointestinal upset.
• Diarrhea: Loose stools occurring shortly after dosing.
• Dry mouth: Reduced salivation leading to oral discomfort.
• Headache: Transient cranial pain.
• Insomnia: Difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Orthostatic hypotension: Marked drop in blood pressure upon standing.
• Hallucinations: Visual or auditory perceptual disturbances.
• Severe constipation: Bowel obstruction risk.
• Elevated liver enzymes: Indicating potential hepatic stress.
• Allergic reactions: Rash, pruritus, or angio‑edema.
• Neuroleptic malignant‑like syndrome: Rare but life‑threatening hyperthermic reaction.

When prescribing Opicapone, clinicians should consider several safety aspects.

• Dose adjustment: Review levodopa dosage to avoid excessive dyskinesia.
• Hepatic function: Monitor liver enzymes periodically, especially in patients with pre‑existing liver disease.
• Cardiovascular status: Observe for signs of orthostatic hypotension.
• Psychiatric history: Watch for emergence of hallucinations or confusion.
• Renal impairment: Use caution in severe renal dysfunction.
• Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Opicapone may alter the pharmacokinetics of several co‑administered medicines, requiring careful management.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: Increased risk of hypertensive crisis.
• Tranylcypromine: Potentiates sympathomimetic effects leading to severe hypertension.
• Certain antihypertensives: May exacerbate orthostatic hypotension when combined.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): May increase serotonergic activity.
• Antipsychotics (Clozapine, Olanzapine): Potential for reduced dopaminergic efficacy.
• Antidiabetic agents: May require dose adjustment due to altered glucose metabolism.